Examining the Long-term Health and Economic Effects of Antimicrobial Resistance in the United States

The National Academies will convene a meeting Examining the Long-term Health and Economic Effects of Antimicrobial Resistance in the United States on March 16-19, 2021 via virtual format.

During these meetings, expert speakers will discuss GARP’s work developing treatments for drug-resistant infections and CMS reimbursement for new antibiotics. Speakers will also present on the challenges of using genomic data for surveillance and the role of next-generation sequencing and predictive modeling.

The following portions of the meeting are open to the public:

• March 16, 2021, 11:00am – 12:05pm ET
• March 19, 2021, 11:00am – 11:45pm ET

The agenda for the open session include a discussion of:

• GARDP and Antimicrobial Development, Jennifer Schneider, Senior Advisor External Affairs, Global Antibiotic R&D, Partnership
• Inpatient Reimbursement and the Antimicrobial Market, Anand Shah, former Deputy Commissioner for Medical and Scientific Affairs, FDA
• Direct, Predictive Application of Sequencing and Informatics, Gautam Dantas, Professor, Washington University School of Medicine

During the closed sessions across both days, the committee members will discuss draft recommendations and conclusions in the following areas:

• Push and Pull Incentives
• International Action
• Health and Economic Burden
• Surveillance